QRXPharma writes off
Thursday, 21 August, 2008
QRxPharma (ASX: QRX) has had to write off $18 million in impairment charges this financial year, resulting in a $36 million deficit in the Brisbane-based company's bottom line.
The company accrued $18.1 million in non-cash impairment charges relating to intellectual property licensed from the University of Alabama.
Share based payment charges also accounted for $3.5 million of the deficit.
The remainder of the deficit is in line with QRxPharma's expectations, and has gone towards commercialising the company's Q8004IR dual-opioid oral analgesic, the company said.
The product is expected to be launched in 2010.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
